Newron Pharmaceuticals SpA (NP5) Price & Analysis

3 Followers

NP5 Stock Chart & Stats

€18.00

€0.27(2.91%)

At close: Jan 09 4:00 PM EST

€18.00

€0.27(2.91%)

Day’s Range― - ―

52-Week Range€7.16 - €34.65

Previous CloseN/A

Volume1.10K

Average Volume (3M)7.13K

Market Cap

€264.15M

Enterprise Value€298.27M

Total Cash (Recent Filing)€28.85M

Total Debt (Recent Filing)€38.13M

Price to Earnings (P/E)―

Beta1.29

Next Earnings

Sep 22, 2026

EPS Estimate

-0.19

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.67

Shares Outstanding20,805,798

10 Day Avg. Volume8,521

30 Day Avg. Volume7,133

Financial Highlights & Ratios

PEG Ratio0.21

Price to Book (P/B)-45.95

Price to Sales (P/S)26.73

P/FCF Ratio15.73

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€47.67

Price Target Upside164.81% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-1.05

Revenue Forecast (FY)€11.92M

Bulls Say, Bears Say

Bulls Say

Strategic Partnership & FundingThe Eisai licensing deal delivered EUR 48m upfront and access to further non-dilutive financing, materially extending runway. A top-tier partner validates the program, reduces commercialization execution risk, and makes near-term development less dependent on equity raises.

Large Global Pivotal ProgramA >1,300 patient global pivotal program diversifies regulatory and geographic risk and increases statistical robustness versus small trials. Multiple simultaneous studies and partner-led Phase III raise the probability of approval and create clearer commercialization pathways.

Strengthened IP / Extended ExclusivityA granted European crystalline-form patent and the prospect of U.S. coverage to 2044 materially improve long-term exclusivity. Stronger IP enhances partner negotiating leverage, supports future royalty streams, and reduces generic competition risk post-approval.

Bears Say

Weak Balance Sheet / Negative EquityNegative equity and substantial debt constrain financial flexibility and raise refinancing and dilution risk. With limited balance-sheet headroom, the company may be forced to seek dilutive capital or cut programs if milestone timing slips or conditional funding is not realized.

Reliance On Conditional FundingA meaningful tranche of near-term funding (EUR 12m) depends on positive trial outcomes, creating a binary financing risk. If pivotal readouts falter or are delayed, projected runway and plans for enrollment/commercial prep could be jeopardized, increasing the likelihood of dilutive raises.

Volatile Revenue & Recurring LossesRevenue is lumpy and milestone-driven, producing volatile top-line and irregular profitability. The company's history of recurring losses and reliance on episodic license income undermines sustainable internal funding for R&D and heightens dependence on partners or capital markets.

Newron Pharmaceuticals SpA News

Newron, FDA in constructive talks over U.S. trial halt for schizophrenia drug Evenamide

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) just unveiled an update. Newron Pharmaceuticals has provided an update after a...

13d ago

Newron Pharma price target lowered to CHF 44 from CHF 48 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Newron Pharma (NWPHF) to CHF 44 from CHF 48 and...

2M ago

FDA halts U.S. recruitment in Newron’s key schizophrenia trial after patient death

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) has issued an update. Newron Pharmaceuticals said the U.S. Food and Drug...

3M ago

Newron Shareholders Back Board Changes at 2026 General Meeting

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) has provided an announcement. Newron Pharmaceuticals reported that shareholders at its 2026...

3M ago

Newron Pharmaceuticals’ Earnings Call Signals Pivotal Year Ahead

Newron Pharmaceuticals SpA (($CH:NWRN)) has held its Q4 earnings call. Read on for the main highlights of the...

4M ago

Newron Pharma price target raised to CHF 48 from CHF 43 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Newron Pharma (NWPHF) to CHF 48 from...

4M ago

Newron bolsters finances as Evenamide enters pivotal global Phase III

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) has provided an announcement. Newron Pharmaceuticals reported a transformative 2025 marked by...

4M ago

Newron Fortifies Evenamide Phase III Push with Fresh Capital, Patent Win and Board Overhaul

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) has issued an update. Newron reported 2025 as a landmark year, driven...

4M ago

Newron to Highlight Phase III Evenamide Data at 2026 Schizophrenia Congress

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) has provided an update. Newron Pharmaceuticals will showcase new data on its...

4M ago

Newron extends EIB loan maturities to align financing with Evenamide milestones

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) has provided an update. Newron Pharmaceuticals has reached an agreement in principle...

4M ago

Newron refreshes board with CNS and capital markets experts ahead of AGM

An announcement from Newron Pharmaceuticals SpA ( ($CH:NWRN) ) is now available. Newron Pharmaceuticals announced upcoming changes to...

4M ago

Newron Raises Up to EUR 38 Million to Advance Phase III Schizophrenia Drug Evenamide

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) has issued an update. Newron Pharmaceuticals has secured commitments of up to...

5M ago

Newron Pharma price target raised to CHF 43 from CHF 26 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Newron Pharma (NWPHF) to CHF 43 from...

6M ago

Newron Pharma initiated with a Buy at Lucid Capital

Lucid Capital analyst Elemer Piros initiated coverage of Newron Pharma (NWPHF) with a Buy rating and CHF 73...

7M ago

NP5 FAQ

What was Newron Pharmaceuticals SpA’s price range in the past 12 months?

Newron Pharmaceuticals SpA lowest stock price was €7.16 and its highest was €34.65 in the past 12 months.

What is Newron Pharmaceuticals SpA’s market cap?

Newron Pharmaceuticals SpA’s market cap is €264.15M.

When is Newron Pharmaceuticals SpA’s upcoming earnings report date?

Newron Pharmaceuticals SpA’s upcoming earnings report date is Sep 22, 2026 which is in 69 days.

How were Newron Pharmaceuticals SpA’s earnings last quarter?

Newron Pharmaceuticals SpA released its earnings results on Mar 24, 2026. The company reported -€0.66 earnings per share for the quarter, missing the consensus estimate of -€0.08 by -€0.58.

Is Newron Pharmaceuticals SpA overvalued?

According to Wall Street analysts Newron Pharmaceuticals SpA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Newron Pharmaceuticals SpA pay dividends?

Newron Pharmaceuticals SpA does not currently pay dividends.

What is Newron Pharmaceuticals SpA’s EPS estimate?

Newron Pharmaceuticals SpA’s EPS estimate is -0.19.

How many shares outstanding does Newron Pharmaceuticals SpA have?

Newron Pharmaceuticals SpA has 20,805,798 shares outstanding.

What happened to Newron Pharmaceuticals SpA’s price movement after its last earnings report?

Newron Pharmaceuticals SpA reported an EPS of -€0.66 in its last earnings report, missing expectations of -€0.08. Following the earnings report the stock price went down -7.177%.

Which hedge fund is a major shareholder of Newron Pharmaceuticals SpA?

Currently, no hedge funds are holding shares in DE:NP5

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Newron Pharmaceuticals SpA

Founded in 1999 and headquartered in Bresso, Italy, Newron Pharmaceuticals S.p.A. is a clinical-stage biopharmaceutical enterprise focused on discovering and progressing therapeutic solutions. Its primary areas of research and development encompass conditions affecting the central and peripheral nervous systems, alongside pain management, with activities primarily conducted in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease and is also exploring its application for levodopa-induced dyskinesia. Furthermore, Newron is advancing Evenamide for various forms of schizophrenia, including those resistant to existing treatments, and Ralfinamide for the rare disease indication of neuropathic pain.

Newron Pharmaceuticals SpA (NP5) Earnings & Revenues

Historic Earnings Reports

NP5 Stock 12 Month Forecast

Average Price Target

€47.67

▲(164.81% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"€6","27":"€27","48":"€48","16.5":"€16.5","37.5":"€37.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":47.666036,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€47.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":47.666036,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€47.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":47.666036,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€47.67</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,16.5,27,37.5,48],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.65,16.266618153846153,18.883236307692307,21.49985446153846,24.116472615384616,26.73309076923077,29.349708923076925,31.96632707692308,34.58294523076923,37.19956338461539,39.81618153846154,42.4327996923077,45.049417846153844,{"y":47.666036,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.65,16.266618153846153,18.883236307692307,21.49985446153846,24.116472615384616,26.73309076923077,29.349708923076925,31.96632707692308,34.58294523076923,37.19956338461539,39.81618153846154,42.4327996923077,45.049417846153844,{"y":47.666036,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.65,16.266618153846153,18.883236307692307,21.49985446153846,24.116472615384616,26.73309076923077,29.349708923076925,31.96632707692308,34.58294523076923,37.19956338461539,39.81618153846154,42.4327996923077,45.049417846153844,{"y":47.666036,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.16,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.41,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":11.78,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":15.9,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":20.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.35,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.65,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.7,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.24,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.85,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.25,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.65,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >